<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Galapagos N.v. — News on 6ix</title>
    <link>https://6ix.com/company/galapagos-nv</link>
    <description>Latest news and press releases for Galapagos N.v. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/galapagos-nv" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68361fc478dffbe2df140ee1.webp</url>
      <title>Galapagos N.v.</title>
      <link>https://6ix.com/company/galapagos-nv</link>
    </image>
    <item>
      <title>Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-and-gilead-enter-into-binding-agreement-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-and-gilead-enter-into-binding-agreement-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases</guid>
      <pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
      <description>New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue</description>
    </item>
    <item>
      <title>Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-publishes-2025-annual-report-and-announces-annual-and-extraordinary-shareholders-meetings</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-publishes-2025-annual-report-and-announces-annual-and-extraordinary-shareholders-meetings</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV (Euronext &amp; NASDAQ: GLPG) today published its annual report for the</description>
    </item>
    <item>
      <title>Galapagos Announces Nomination of Gino Santini to its Board of Directors</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-announces-nomination-of-gino-santini-to-its-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-announces-nomination-of-gino-santini-to-its-board-of-directors</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive</description>
    </item>
    <item>
      <title>Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-and-gilead-in-advanced-discussions-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-and-gilead-in-advanced-discussions-to-collaborate-on-advancing-first-in-class-t-cell-engager-program-for-autoimmune-diseases</guid>
      <pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
      <description>Galapagos intends to enter into a strategic collaboration with Gilead following Gilead&apos;s acquisition of Ouro Medicines New partnership structure would achieve</description>
    </item>
    <item>
      <title>Galapagos Receives Transparency Notifications from Bank of America   </title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-receives-transparency-notifications-from-bank-of-america-62</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-receives-transparency-notifications-from-bank-of-america-62</guid>
      <pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
      <description>Mechelen, Belgium; March 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext &amp; NASDAQ: GLPG) received transparency notifications from Bank of</description>
    </item>
    <item>
      <title>Galapagos Appoints Tania Philipp as Chief Human Resources Officer</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-appoints-tania-philipp-as-chief-human-resources-officer-31</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-appoints-tania-philipp-as-chief-human-resources-officer-31</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>Seasoned Life Sciences Executive Joins Galapagos with Strong Track Record in Change Management Mechelen, Belgium; March 5, 2026, 22:01 CET — Galapagos NV</description>
    </item>
    <item>
      <title>Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-reports-full-year-2025-financial-results-and-provides-fourth-quarter-business-update</guid>
      <pubDate>Mon, 23 Feb 2026 21:01:00 GMT</pubDate>
      <description>Strategic reset positions Galapagos for long-term value creation Robust 2025 year-end cash and financial investments of €3.0 billion and ongoing collaboration with Gilead enable flexibility to execute on a business development-led growth strategy 2026 year-end cash expected to be in the range of €2.775 to €2.850 billion, with reduced cell therapy one-time restructuring cash costs of €25 million to an updated range of €125 to €175 million Management to host conference call tomorrow, February 24,</description>
    </item>
    <item>
      <title>Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-welcomes-dr-paulo-fontoura-to-its-board-of-directors</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-welcomes-dr-paulo-fontoura-to-its-board-of-directors</guid>
      <pubDate>Thu, 19 Feb 2026 21:01:00 GMT</pubDate>
      <description>Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET — Galapagos NV (Euronext &amp; NASDAQ: GLPG), today announced the appointment by way of co-optation of Dr. Paulo Fontoura as Non-Executive Independent Director to its Board of Directors, effective February 9, 2026. “We are pleased to welcome Paulo to our Board,” said Jérôme Contamine, Chair of the Board of Galapagos. “His global leadership exp</description>
    </item>
    <item>
      <title>Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors   </title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-welcomes-dr-paulo-fontoura-to-its-board-of-directors-1</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-welcomes-dr-paulo-fontoura-to-its-board-of-directors-1</guid>
      <pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
      <description>Dr. Fontoura brings extensive global leadership, clinical development, and operational experience to the Board Mechelen, Belgium; February 19, 2026, 22:01 CET</description>
    </item>
    <item>
      <title>Galapagos Receives Transparency Notification from Bank of America</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-receives-transparency-notification-bank-210100715</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-receives-transparency-notification-bank-210100715</guid>
      <pubDate>Mon, 16 Feb 2026 21:01:00 GMT</pubDate>
      <description>Mechelen, Belgium; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext &amp; NASDAQ: GLPG) received a transparency notification from Bank of America. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on February 11, 2026, from Bank of America Corporation. The notification indicates that Bank of America Corporation, as controlling entity, crossed above the threshold of 5% of Galapagos’ voting rights on February 9, 2026, including th</description>
    </item>
    <item>
      <title>Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-announces-board-decision-initiate-wind-down-cell-therapy-activities-2026-0</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-announces-board-decision-initiate-wind-down-cell-therapy-activities-2026-0</guid>
      <pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
      <description>Mechelen, Belgium; January 5, 2026, 22:01 CET; Galapagos NV (Euronext &amp; NASDAQ: GLPG) today announced that the works council consultation process regarding</description>
    </item>
    <item>
      <title>Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-announces-topline-results-two-phase-3-enabling-studies-selective-tyk2-0</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-announces-topline-results-two-phase-3-enabling-studies-selective-tyk2-0</guid>
      <pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
      <description>GLPG3667 met primary endpoint in dermatomyositis study, demonstrating a statistically significant clinical benefit and meaningful improvements on secondary</description>
    </item>
    <item>
      <title>Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-presented-new-atalanta-1-cell-therapy-data-mcl-ash-2025-2025-12-08-0</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-presented-new-atalanta-1-cell-therapy-data-mcl-ash-2025-2025-12-08-0</guid>
      <pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
      <description>High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a</description>
    </item>
    <item>
      <title>Galapagos Receives Transparency Notifications from Bank of America</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-receives-transparency-notifications-bank-america-2025-11-26-0</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-receives-transparency-notifications-bank-america-2025-11-26-0</guid>
      <pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
      <description>Mechelen, Belgium; November 26, 2025, 07:30 CET; regulated information – Galapagos NV (Euronext &amp; NASDAQ: GLPG) received transparency notifications from Bank</description>
    </item>
    <item>
      <title>Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-reports-nine-months-2025-financial-results-and-provides-business-update-0</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-reports-nine-months-2025-financial-results-and-provides-business-update-0</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger</description>
    </item>
    <item>
      <title>Galapagos to Present New Data from Cell Therapy Program at ASH 2025</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-present-new-data-cell-therapy-program-ash-2025-2025-11-03-0</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-present-new-data-cell-therapy-program-ash-2025-2025-11-03-0</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>Oral presentation of GLPG5101 data from the ATALANTA-1 study in patients with high-risk relapsed/refractory mantle cell lymphoma Two abstracts featuring new</description>
    </item>
    <item>
      <title>Galapagos Announces Changes to its Board to Accelerate Strategic Focus on Business Development</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-announces-changes-its-board-accelerate-strategic-focus-business-0</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-announces-changes-its-board-accelerate-strategic-focus-business-0</guid>
      <pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
      <description>New Directors bring strong financial leadership, capital allocation, and business development expertise to the Board Mechelen, Belgium; October 30, 2025,</description>
    </item>
    <item>
      <title>Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-present-vitro-data-acr-convergence-2025-suggesting-differentiation-0</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-present-vitro-data-acr-convergence-2025-suggesting-differentiation-0</guid>
      <pubDate>Thu, 23 Oct 2025 04:00:00 GMT</pubDate>
      <description>Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext &amp; NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data</description>
    </item>
    <item>
      <title>Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-announces-intention-wind-down-cell-therapy-business-part-companys-ongoing-0</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-announces-intention-wind-down-cell-therapy-business-part-companys-ongoing-0</guid>
      <pubDate>Tue, 21 Oct 2025 04:00:00 GMT</pubDate>
      <description>Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable</description>
    </item>
    <item>
      <title>Galapagos Announces Appointment of Fred Blakeslee as General Counsel</title>
      <link>https://6ix.com/company/galapagos-nv/news/galapagos-announces-appointment-fred-blakeslee-general-counsel-2025-10-16-0</link>
      <guid isPermaLink="true">https://6ix.com/company/galapagos-nv/news/galapagos-announces-appointment-fred-blakeslee-general-counsel-2025-10-16-0</guid>
      <pubDate>Thu, 16 Oct 2025 04:00:00 GMT</pubDate>
      <description>Mechelen, Belgium; October 16, 2025, 22:01 CET; Galapagos NV (Euronext &amp; NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice</description>
    </item>
  </channel>
</rss>